Nature's Sunshine Products (NATR) Competitors

$19.10
+0.04 (+0.21%)
(As of 05/6/2024 ET)

NATR vs. VSTM, VERU, ADCT, HROW, ESPR, RVNC, AMRN, LXRX, MREO, and HRTX

Should you be buying Nature's Sunshine Products stock or one of its competitors? The main competitors of Nature's Sunshine Products include Verastem (VSTM), Veru (VERU), ADC Therapeutics (ADCT), Harrow Health (HROW), Esperion Therapeutics (ESPR), Revance Therapeutics (RVNC), Amarin (AMRN), Lexicon Pharmaceuticals (LXRX), Mereo BioPharma Group (MREO), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical preparations" industry.

Nature's Sunshine Products vs.

Verastem (NASDAQ:VSTM) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.

In the previous week, Nature's Sunshine Products had 2 more articles in the media than Verastem. MarketBeat recorded 2 mentions for Nature's Sunshine Products and 0 mentions for Verastem. Verastem's average media sentiment score of 1.07 beat Nature's Sunshine Products' score of 0.00 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company Overall Sentiment
Verastem Neutral
Nature's Sunshine Products Positive

Verastem received 433 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 65.20% of users gave Verastem an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.

CompanyUnderperformOutperform
VerastemOutperform Votes
594
65.20%
Underperform Votes
317
34.80%
Nature's Sunshine ProductsOutperform Votes
161
62.89%
Underperform Votes
95
37.11%

Nature's Sunshine Products has a net margin of 3.39% compared to Nature's Sunshine Products' net margin of 0.00%. Verastem's return on equity of 12.25% beat Nature's Sunshine Products' return on equity.

Company Net Margins Return on Equity Return on Assets
VerastemN/A -127.00% -54.73%
Nature's Sunshine Products 3.39%12.25%7.75%

88.4% of Verastem shares are held by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are held by institutional investors. 2.2% of Verastem shares are held by company insiders. Comparatively, 4.9% of Nature's Sunshine Products shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nature's Sunshine Products has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verastem$2.60M115.26-$87.37M-$4.10-2.89
Nature's Sunshine Products$445.32M0.81$15.08M$0.7724.81

Verastem has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Nature's Sunshine Products has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Verastem presently has a consensus price target of $28.79, suggesting a potential upside of 143.12%. Nature's Sunshine Products has a consensus price target of $24.00, suggesting a potential upside of 25.65%. Given Nature's Sunshine Products' higher probable upside, equities research analysts plainly believe Verastem is more favorable than Nature's Sunshine Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verastem
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nature's Sunshine Products
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Nature's Sunshine Products beats Verastem on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NATR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NATR vs. The Competition

MetricNature's Sunshine ProductsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$359.46M$6.45B$4.86B$7.75B
Dividend YieldN/A2.76%5.30%3.96%
P/E Ratio24.8118.24161.0917.78
Price / Sales0.81304.702,401.7486.74
Price / Cash11.9520.0633.2128.53
Price / Book2.285.734.934.42
Net Income$15.08M$136.35M$102.37M$214.66M
7 Day Performance-1.80%4.65%3.06%2.96%
1 Month Performance-3.24%-4.14%-2.82%-1.81%
1 Year Performance77.51%4.38%5.98%10.23%

Nature's Sunshine Products Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VSTM
Verastem
1.4786 of 5 stars
$9.98
+3.6%
$28.79
+188.4%
+130.0%$252.59M$2.60M-2.4373Upcoming Earnings
VERU
Veru
1.154 of 5 stars
$1.35
+8.0%
$3.33
+146.9%
+22.4%$197.61M$16.30M-1.80189Upcoming Earnings
Analyst Report
News Coverage
ADCT
ADC Therapeutics
3.1168 of 5 stars
$4.40
-2.2%
$7.50
+70.5%
+127.0%$364.36M$69.56M-1.50273News Coverage
HROW
Harrow Health
2.6447 of 5 stars
$10.19
-4.0%
$28.13
+176.1%
-61.3%$360.35M$130.19M-13.59182Upcoming Earnings
Positive News
ESPR
Esperion Therapeutics
3.7268 of 5 stars
$1.97
-1.0%
$9.33
+373.8%
+51.4%$373.12M$116.33M-0.93240
RVNC
Revance Therapeutics
4.0733 of 5 stars
$3.61
-2.2%
$13.75
+280.9%
-88.2%$376.23M$234.04M-0.95597Upcoming Earnings
AMRN
Amarin
0.6869 of 5 stars
$0.92
+4.5%
$1.08
+17.6%
-29.5%$378.19M$306.91M-6.58275Earnings Report
LXRX
Lexicon Pharmaceuticals
2.0546 of 5 stars
$1.54
-1.3%
$5.00
+224.7%
-47.6%$379.21M$1.20M-1.92285Analyst Revision
MREO
Mereo BioPharma Group
2.0387 of 5 stars
$3.05
+10.5%
$6.50
+113.1%
+158.3%$381.22M$10M0.0033Positive News
HRTX
Heron Therapeutics
3.7072 of 5 stars
$2.32
-7.2%
$5.50
+137.1%
+15.0%$348.77M$127.04M-2.70126

Related Companies and Tools

This page (NASDAQ:NATR) was last updated on 5/7/2024 by MarketBeat.com Staff

From Our Partners